Skip to content

Study · Animal study (in vivo) · rat · 2002

6 results

Pentadecapeptide BPC 157 attenuates chronic amphetamine-induced behavior disturbances.

Sikiric P, Jelovac N, Jelovac-Gjeldum A, Dodig G, Staresinic M, Anic T, Zoricic I, Rak D, Perovic D, Aralica G, Buljat G, Prkacin I and 11 more

Show all authors

Lovric-Bencic M, Separovic J, Seiwerth S, Rucman R, Petek M, Turkovic B, Ziger T, Boban-Blagaic A, Bedekovic V, Tonkic A, Babic S

Acta pharmacologica Sinica1 May 2002Cited by 21 (Europe PMC)

PMID11978191 (opens in a new tab)PepBankPUB-11978191
Publisher pageAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, the higher BPC‑157 dose attenuated stereotyped behavior after the initial amphetamine application versus saline.

    In plain wordsIn rats, the higher BPC‑157 dose reduced repeated stereotyped movements after amphetamine compared with saline.

    Peptide
    BPC-157
    Outcome
    DecreaseStereotyped behavior after initial amphetamine (higher dose)
    Study

    ratn: not reported in source

    chronic amphetamine exposure
    Comparator
    Saline
    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    10 µg/kg · intraperitoneal · single dose at the startAs given in this study (rat).

    Source sentences

    Summary
    the higher BPC 157 dosage apparently attenuated the stereotyped behavior
    2 context sentences
    Summary · context
    To investigate the effect of pentadecapeptide BPC 157 on chronic exposure to amphetamine in rats, particularly the changes commonly referred in chronic amphetamine studies as tolerance (lesser grade of stereotyped behavior, without increased excitability) and reverse tolerance (ie, prominent stereot…
    Summary · context
    Pentadecapeptide BPC 157 (10 microg/kg or 10 ng/k g, ip) or saline (5.0 mL/kg, ip) were given only at the beginning of the experiment, simultaneously with the initial dose of amphetamine.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats, the lower BPC‑157 dose did not reach statistical significance for stereotyped behavior after the initial amphetamine application.

    In plain wordsIn rats, the lower BPC‑157 dose did not show a statistically significant effect on stereotyped movements after amphetamine.

    Peptide
    BPC-157
    Outcome
    No significant changeStereotyped behavior after initial amphetamine (lower dose)
    Study

    ratn: not reported in source

    chronic amphetamine exposure
    Comparator
    Saline
    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    10 ng/kg · intraperitoneal · single dose at the startAs given in this study (rat).

    Source sentences

    Summary
    while the lower dosage of BPC 157 did not reach a statistical significance.
    2 context sentences
    Summary · context
    To investigate the effect of pentadecapeptide BPC 157 on chronic exposure to amphetamine in rats, particularly the changes commonly referred in chronic amphetamine studies as tolerance (lesser grade of stereotyped behavior, without increased excitability) and reverse tolerance (ie, prominent stereot…
    Summary · context
    Pentadecapeptide BPC 157 (10 microg/kg or 10 ng/k g, ip) or saline (5.0 mL/kg, ip) were given only at the beginning of the experiment, simultaneously with the initial dose of amphetamine.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats given BPC‑157 at the first amphetamine dose, stereotyped behavior stayed attenuated after all later amphetamine challenges, at either BPC‑157 dose.

    In plain wordsIn rats given BPC‑157 with the first amphetamine dose, stereotyped movements stayed lower after later amphetamine doses.

    Peptide
    BPC-157
    Outcome
    DecreaseStereotyped behavior after later amphetamine challenges
    Study

    ratn: not reported in source

    chronic amphetamine exposure
    Comparator
    Saline
    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    10 µg/kg or 10 ng/kg · intraperitoneal · single dose at the startAs given in this study (rat).

    Source sentences

    Summary
    Considering the forthcoming amphetamine challenges, in the rats initially treated with pentadecapeptide BPC 157, either 10 microg- or 10 ng-dose, at the time of the first application of amphetamine, the stereotyped behavior remains to be attenuated after all additional amphetamine challenges (on d 2-5, 8, 16, and 46).
    2 context sentences
    Summary · context
    To investigate the effect of pentadecapeptide BPC 157 on chronic exposure to amphetamine in rats, particularly the changes commonly referred in chronic amphetamine studies as tolerance (lesser grade of stereotyped behavior, without increased excitability) and reverse tolerance (ie, prominent stereot…
    Summary · context
    Pentadecapeptide BPC 157 (10 microg/kg or 10 ng/k g, ip) or saline (5.0 mL/kg, ip) were given only at the beginning of the experiment, simultaneously with the initial dose of amphetamine.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats, BPC‑157 at either dose mitigated the heightened startle response after the initial amphetamine application.

    In plain wordsIn rats, BPC‑157 at either dose reduced the heightened startle response after amphetamine.

    Peptide
    BPC-157
    Outcome
    DecreaseHeightened startle response after initial amphetamine
    Study

    ratn: not reported in source

    chronic amphetamine exposure
    Comparator
    Saline
    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    10 µg/kg or 10 ng/kg · intraperitoneal · single dose at the startAs given in this study (rat).

    Source sentences

    Summary
    After the initial application of the amphetamine the heighten ed startle response was also apparently mitigated in rats receiving the BPC 157 dosage, either higher or lower.
    2 context sentences
    Summary · context
    To investigate the effect of pentadecapeptide BPC 157 on chronic exposure to amphetamine in rats, particularly the changes commonly referred in chronic amphetamine studies as tolerance (lesser grade of stereotyped behavior, without increased excitability) and reverse tolerance (ie, prominent stereot…
    Summary · context
    Pentadecapeptide BPC 157 (10 microg/kg or 10 ng/k g, ip) or saline (5.0 mL/kg, ip) were given only at the beginning of the experiment, simultaneously with the initial dose of amphetamine.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats given BPC‑157 at the first amphetamine dose, abnormal excitability was less at all tested points after later amphetamine challenges.

    In plain wordsIn rats given BPC‑157 with the first amphetamine dose, abnormal excitability stayed lower after later amphetamine doses.

    Peptide
    BPC-157
    Outcome
    DecreaseAbnormal excitability after later amphetamine challenges
    Study

    ratn: not reported in source

    chronic amphetamine exposure
    Comparator
    Saline
    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    10 µg/kg or 10 ng/kg · intraperitoneal · single dose at the startAs given in this study (rat).

    Source sentences

    Summary
    Later, confronted with the forthcoming amphetamine challenges, they showed apparently less abnormal excitability at all tested points.
    2 context sentences
    Summary · context
    To investigate the effect of pentadecapeptide BPC 157 on chronic exposure to amphetamine in rats, particularly the changes commonly referred in chronic amphetamine studies as tolerance (lesser grade of stereotyped behavior, without increased excitability) and reverse tolerance (ie, prominent stereot…
    Summary · context
    Pentadecapeptide BPC 157 (10 microg/kg or 10 ng/k g, ip) or saline (5.0 mL/kg, ip) were given only at the beginning of the experiment, simultaneously with the initial dose of amphetamine.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats, BPC‑157 at both doses attenuated chronic amphetamine disturbances throughout the observation period at a statistically significant level.

    In plain wordsIn rats, BPC‑157 at both doses reduced the behavior changes caused by repeated amphetamine.

    Peptide
    BPC-157
    Outcome
    DecreaseChronic amphetamine disturbances overall
    Study

    ratn: not reported in source

    chronic amphetamine exposure
    Comparator
    Saline
    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    10 µg/kg or 10 ng/kg · intraperitoneal · single dose at the startAs given in this study (rat).

    Source sentences

    Summary
    In summary, gastric pentadecapeptide BPC 157 (ie, both microg- and ng-BPC 157 regimens) attenuated chronic amphetamine disturbances. This effect was present throughout the observation period at a statistically significant level.
    2 context sentences
    Summary · context
    To investigate the effect of pentadecapeptide BPC 157 on chronic exposure to amphetamine in rats, particularly the changes commonly referred in chronic amphetamine studies as tolerance (lesser grade of stereotyped behavior, without increased excitability) and reverse tolerance (ie, prominent stereot…
    Summary · context
    Pentadecapeptide BPC 157 (10 microg/kg or 10 ng/k g, ip) or saline (5.0 mL/kg, ip) were given only at the beginning of the experiment, simultaneously with the initial dose of amphetamine.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.